GoodCell Diagnostic focuses on turning blood into actionable data both for individuals and populations in real time and over time through biobanking. We exploit the power of biological data to create an analytic pipeline to inform individual health, doctors’ decisions, commercial institutions to enhance their testing capabilities and each step of the cell manufacturing process to create emerging therapies.
Using genetic analysis, of both inherited variants and acquired mutations as well as in depth interrogation of biomarkers in blood, GoodCell Diagnostics has the opportunity to develop unique applications for quantifying risk and measuring cell quality. We offer the potential to extend and improve quality of life and assure the best quality of cellular materials for future therapeutic applications by decoding the essential components of human health contained in our blood—DNA and biomarkers.
Emerging biological science and data science form the core of our platform, creating the opportunity on which we are building, backed by some of the top physicians and scientists in the field.
GoodCell is investigating and advancing additional applications for genetic detection of acquired (somatic) variations (sequence and structure based) unique to blood stem cells and other nucleated cells in blood. These accumulated variations have been linked to higher risk for certain blood cancers, heart disease and dysfunctional response to inflammation and infection.
Cell Quality Assessment
Cell therapies largely originate from cells derived from blood – HSC’s, iPSCs and T-cells. While somewhat protected from mutation by being inside the human body, our blood cells inevitably accumulate genetic change/damage as we age. This accumulated damage comes with risk for disease and reduced potential to utilize these cells for therapeutic application.
Patients who could benefit from cell therapies, pharmaceutical firms developing those therapies, researchers investigating those therapies and contract cell therapy manufacturers making those therapies all want the highest quality, least damaged cells possible as starting material. Avoiding cells with these mutations is a good place to start in that quest.
GoodCell affords the opportunity to biobank an individual’s youngest healthiest cells – preserving their potential for the future. In parallel, GoodCell, with its genetic assay is uniquely able to quantify and track damage to these cells that accumulates over time and through processing for potential therapies. This genetic assay can offer the same assurance to companies developing and manufacturing cell therapies. It can provide public health officials with population risk assessments as well.
Most of the severe morbidity and mortality seen in COVID19 stems from the inflammation of a runaway immune response. Research has linked certain genetic variations included in our genetic assay to a dysfunctional response to inflammation and infection, and because of the normal age distribution of those mutations, it is highly likely that individuals with them are at higher risk of the most severe COVID19 outcomes.
If through clinical partnerships this link can be proven, GoodCell could provide quantifiable risk assessment. This could form a data platform that could benefit public health officials looking to isolate the most vulnerable and help clinicians more effectively manage the mutation related comorbidities in COVID19, including acute respiratory distress syndrome (ARDS), lung injury, venous thrombosis and acute cardiac injury.
At GoodCell’s Diagnostics division we are defining new ways for quantifying risk and we’re setting the standard of cell quality, delivering the best data and cells to researchers, clinicians, and patients when they need them.
GoodCell Diagnostics seeks partners developing cell therapies to work at several points in the development process. Up front, we make sure the best cells form the starting material; then monitor mutations that develop during cell manipulation and optimize manufacturing to minimize this; and assure the end product cell quality.
If you are interested in partnering, contact us.